Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-0000-17-424-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.
Despite substantial progress in improving the rates of VTE prophylaxis, hospital-related
VTE continues to occur at a steady rate. New data are emerging in support of extended
prophylaxis in hospitalized patients, particularly those hospitalized with medical
problems. Indeed, a shift toward continuing VTE prophylaxis after hospital discharge
may hold the key to lowering the rates of hospital-related VTE, especially given the
availability of oral, rather than injectable, administration.
Health-system pharmacists have been important contributors to the increased use of VTE prophylaxis in hospitals over the last decade. As new data emerge on extended VTE prophylaxis, pharmacists will be called upon to manage new initiatives for VTE prevention and ensure safe patient transitions to outpatient care. As such, it is particularly important that pharmacists be well informed about the latest evidence, knowledgeable about all available treatment options, and cognizant of the barriers that exist to implementing best practices.
In this activity, attendees will learn strategies for improving VTE prevention in hospitalized patients. The discussion will also cover advantages and disadvantages of current vs new pharmacologic options for VTE prevention and management and the pharmacist’s role in transitioning patients from the inpatient to the outpatient setting for extended VTE prophylaxis.
The target audience for this activity includes pharmacists in health-system settings. After completing the activity, participants should be able to:
Paul P. Dobesh, Pharm.D., FCCP, BCPS – AQ Cardiology
Professor of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
John Fanikos, RPh, MBA
Director of Pharmacy Business
Brigham & Women’s Hospital
ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-18-016-H01-P has been assigned to this home study knowledge-based activity (initial release date 1-29-18). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed during their presentation. Dr. Dobesh is
a Consultant for Boehringer Ingelheim, Daiichi Sankyo, Inc., Janssen Pharmaceuticals,
Pfizer/BMS Alliance, and Portola Pharmaceuticals. Mr. Fanikos is a Consultant for
Portola Pharmaceuticals. A portion of grant funds received by ProCE from Portola Pharmaceuticals
will be used to compensate the faculty for this presentation.
Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
This activity is provided by ProCE, Inc. and is supported by an educational grant from Portola Pharmaceuticals.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.